Natalizumab: a double-edged sword?
Lisa M
LM
DeAngelis
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D016543:Central Nervous System Neoplasms / Q000139:chemically induced* / Q000175:diagnosis; D003937:Diagnosis, Differential; D003951:Diagnostic Errors; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced; D008223:Lymphoma / Q000139:chemically induced* / Q000175:diagnosis; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy*; D000069442:Natalizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab